
USD
+$0.00
(+0.00%
)At Close (As of Dec 10, 2025)
$293.59M
Market Cap
-
P/E Ratio
-4.2
EPS
$20.90
52 Week High
$7.00
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $81M |
| Total Revenue | $229M |
| Cost Of Revenue | $147M |
| Costof Goods And Services Sold | $147M |
| Operating Income | -$92M |
| Selling General And Administrative | $73M |
| Research And Development | $21M |
| Operating Expenses | $173M |
| Investment Income Net | - |
| Net Interest Income | $13M |
| Interest Income | $13M |
| Interest Expense | $7K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $3M |
| Income Before Tax | -$77M |
| Income Tax Expense | $5M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$82M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$77M |
| Ebitda | -$74M |
| Net Income | -$82M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $81M |
| Total Revenue | $229M |
| Cost Of Revenue | $147M |
| Costof Goods And Services Sold | $147M |
| Operating Income | -$92M |
| Selling General And Administrative | $73M |
| Research And Development | $21M |
| Operating Expenses | $173M |
| Investment Income Net | - |
| Net Interest Income | $13M |
| Interest Income | $13M |
| Interest Expense | $7K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $3M |
| Income Before Tax | -$77M |
| Income Tax Expense | $5M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$82M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$77M |
| Ebitda | -$74M |
| Net Income | -$82M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Amarin Corporation PLC is a Dublin-based biopharmaceutical company focused on developing and commercializing innovative therapies for cardiovascular diseases, with a primary emphasis on the U.S. market. Its flagship product, Vascepa, is a prescription medication recognized for its efficacy in significantly lowering triglyceride levels among patients with elevated cardiovascular risk. The company is committed to advancing its research pipeline, exploring new clinical applications for Vascepa, and expanding market access to strengthen its foothold within the cardiovascular health sector. With a strategic focus on innovation and patient outcomes, Amarin is poised to remain a significant contributor to advancements in cardiovascular therapeutics.